SAN DIEGO, November 5, 2007 — Conatus Pharmaceuticals Inc. today reported positive preclinical results on its lead compound, CTS-1027 in multiple models of hepatitis, an inflammatory liver disease. The results were presented in a poster session today at the American Association for the Study of Liver Diseases (AASLD) in Boston, MA. CTS-1027 significantly reduced liver […]
Blog: Press, Pharma News, Drug Reviews
SAN DIEGO, November 1, 2011 — Conatus Pharmaceuticals Inc. announced today the appointment of Gary Craig Burgess, M.B., Ch.B. MMed, as Senior Vice President and Chief Medical Officer effective immediately. In this newly created position, Dr. Burgess will oversee all of the company’s clinical development activities. “I am delighted to welcome Gary to the Conatus […]
SAN DIEGO, October 25, 2011 — Conatus Pharmaceuticals Inc. announced today the termination of its Phase 2 clinical trial of CTS-1027 in HCV patients. This decision follows reports of laboratory abnormalities and adverse events in a subset of clinical trial participants. The top priority of Conatus is patient safety, and the Company has made the […]
SAN DIEGO, August 24, 2006 — Conatus Pharmaceuticals Inc. today announced that it has relocated the corporate operations to 4365 Executive Drive, Suite 200, San Diego, CA 92121. The main telephone number is 858-558-8130 and the facsimile number, 858-558-8920. “We are pleased to have secured a premium location in the University Towne Centre section of […]
SAN DIEGO, August 24, 2006 — Conatus Pharmaceuticals Inc. today announced that it has retained the services of new personnel that complete the key team of technical and business expertise. Joining Conatus is Patricia Contreras, Ph.D., MiRa Huyghe, Sharon Platt and Karen Valentino, Ph.D. “We are pleased to have these critically important personnel join Conatus,” […]
SAN DIEGO, October 5, 2009 — Conatus Pharmaceuticals Inc., a privately held, clinical stage company developing a treatment for liver disease associated with Hepatitis C Virus (HCV), announced today that Steven J. Mento, Ph.D., President and Chief Executive Officer, will present at the Montgomery Healthcare Conference being held in Menlo Park, CA, on October 6, […]
Former Idun Management team to expand efforts in liver disease and oncology SAN DIEGO, July 30, 2010 — Conatus Pharmaceuticals Inc. announced today that Conatus acquired the Idun Pharmaceuticals subsidiary of Pfizer Inc. Financial terms were not disclosed. Conatus Pharmaceuticals is a privately-held drug development company focused on liver disease and oncology. Conatus Pharmaceuticals is […]
SAN DIEGO, July 12, 2012 — Conatus Pharmaceuticals Inc. announced today the appointment of Mark F. Morris as Head of Biostatistics effective immediately. In this newly created position, Mr. Morris will oversee the statistical design of the company’s human clinical trials. “Mark provides an enormous amount of technical expertise in statistical design and analysis,” said […]
SAN DIEGO, June 24, 2009 — Conatus Pharmaceuticals Inc. announced today the initiation of a second Phase 2 clinical trial with a novel drug candidate for the treatment of liver disease associated with Hepatitis C Virus (HCV) infection. The trial will enroll patients for whom treatment with approved standard of care treatments is not currently […]
SAN DIEGO, May 09, 2007 — Conatus Pharmaceuticals Inc. today completed the $22 million second closing of the $27.5 million Series A Preferred Stock private placement announced in January this year. This closing is associated with the achievement of a pre-clinical milestone with CTS-1027, the Company’s novel clinical stage drug candidate. “CTS-1027 is a potent […]